Squamous cell carcinoma arising in mature cystic teratoma of the ovary: report of two cases with molecular analysis

Mature cystic teratoma (MCT) is the most frequent ovarian tumor and it is generally composed of well-differentiated elements which, nevertheless, have the potential for malignant transformation. The authors report two cases of squamous cell carcinoma (SCC) arising on ovarian MCT. In the present study, no mutation of the CDKN2A gene, whose impairment may deeply affect either the p16CDKN2A-Cy-clinD1-pRb cascade or the p14CDKN2A-mdm2-p53 cascade, was observed in tumour tissues from our cases’ collection. This suggests that changes in the protein levels for the above-described candidate effectors may be somehow due to epigenetic alterations into the mechanisms controlling their expression. Analogously, no genetic modification among the two main genes (EGFR and KRAS) upstream the MAPK signalling pathway, which has been widely reported to play a major role in both development and progression of vast majority of malignant tumours, was detected in this series. Additional genes and pathways should be therefore investigated in order to identify genomic impairments underlying the MCT malignant transformation.

Ovary; Mature Cystic teratoma (MCT); Squamous Cell carcinoma (SCC); Double-colour FISH analysis.

[1] Futagami M., Yokoyama Y., Mizukami H., Shigeto T., Mizunuma H.: “Can malignant transformation in mature cystic teratoma be preoperatively predicted?”. Eur. J. Gynaecol. Oncol., 2012, 33, 662.

[2] Ulker V., Numanoglu C., Akbayir O., Akyol A., Tuncel A., Akca A., Aydin O.: “Malignant transformation arising from mature cystic teratoma of the ovary: a report of six cases”. J. Obstet. Gynaecol. Res., 2012, 38, 849.

[3] Peterson W.F.: “Malignant degeneration of benign cystic teratomas of the overy; a collective review of the literature”. Obstet. Gynecol. Surv., 1957, 12, 793.

[4] Bal A., Mohan H., Singh S.B., Sehgal A.: “Malignant transformation in mature cystic teratoma of the ovary: report of five cases and review of the literature”. Arch. Gynecol. Obstet., 2007, 275, 179.

[5] Iwasa A., Oda Y., Kurihara S., Ohishi Y., Yasunaga M., Nishimura I., Takagi E., Kobayashi H., Wake N., Tsuneyoshi M.: “Malignant transformation of mature cystic teratoma to squamous cell carcinoma involves altered expression of p53- and p16/Rb-dependent cell cycle regulator proteins”. Pathol. Int., 2008, 58, 757.

[6] Filippakis G.M., Lagoudianakis E.E., Genetzakis M., Antonakis P., Papadima A., Boussiotou A., Katergiannakis V., Manouras A.: “Squamous cell carcinoma arising in a mature cystic teratoma of the ovary with synchronous invasive lobular breast cancer: case report”. Eur. J. Gynaecol. Oncol., 2006, 27, 537.

[7] Kikkawa F., Nawa A., Tamakoshi K., Ishikawa H., Kuzuya K., Suganuma N., Hattori S., Furui K., Kawai M., Arii Y.: “Diagnosis of squamous cell carcinoma arising from mature cystic teratoma of the ovary”. Cancer, 1998, 82, 2249.

[8] Mahe E., Sur M.: “Squamous lesions of the ovary”. Arch. Pathol. Lab. Med., 2011, 135, 1611.

[9] Hackethal A., Brueggmann D., Bohlmann M.K., Franke F.E., Tin-neberg H.R., Münstedt K.: “Squamouscell carcinoma in mature cystic teratoma of the ovary: systematic review and analysis of published data”. Lancet Oncol., 2008, 9, 1173.

[10] Pomerantz J., Schreiber-Agus N., Lie´ geois N.J.: “The Ink4a tumor suppressor gene product, 19Arf, interacts with MDM2 and neutralizes DM2’s inhibition of p53”. Cell, 1998, 92, 713.

[11] Vogelstein B., Kinzler K.W: “Cancer genes and the pathways they control”. Nat. Med., 2004, 10, 789.

[12] Sini M.C., Manca A., Cossu A., Budroni M., Botti G., Ascierto P.A., Cremona F., Muggiano A., D’Atri S., Casula M., Baldinu P., Palomba G., Lissia A., Tanda F., Palmieri G.: “Molecular alterations at chromosome 9p21 in melanocytic nevi and melanoma”. Br. J. Dermatol., 2008, 158, 243.

[13] Savitchi E., Rao S.: “Squamous cell carcinoma and pleomorphic sarcoma (MFH) arising in a mature cystic teratoma of the ovary”. Int. J. Gynecol. Pathol., 2012, 31, 443.

[14] Futagami M., Yokoyama Y., Mizukami H., Shigeto T., Mizunuma H.: “Can malignant transformation in mature cystic teratoma be preoperatively predicted?”. Eur. J. Gynaecol. Oncol., 2012, 33, 662.

[15] Mori Y., Nishii H., Takabe K., Shinozaki H., Matsumoto N., Suzuki K., Tanabe H., Watanabe A., Ochiai K., Tanaka T.: “Preoperative diagnosis of malignant transformation arising from mature cystic teratoma of the ovary”. Gynecol. Oncol., 2003, 90, 338.

[16] Suzuki M., Kobayashi H., Ohwada M., Terao T., Sato I.: “Macrophage colonystimulating factor as a marker for malignant germ cell tumors of the ovary”. Gynecol. Oncol., 1998, 68, 35.

[17] Park S.B., Kim J.K., Kim K.R., Cho K.S.: “Preoperative diagnosis of mature cystic teratoma with malignant transformation: analysis of imaging findings and clinical and laboratory data”. Arch. Gynecol. Obstet., 2007, 275, 25.

[18] Sakuma M., Otsuki T., Yoshinaga K., Utsunomiya H., Nagase S., Takano T., Niikura H., Ito K., Otomo K., Tase T., Watanabe Y., Yaegashi N.: “Malignant transformation arising from mature cystic teratoma of the ovary: a retrospective study of 20 cases”. Int. J. Gynecol. Cancer, 2010, 20, 766.

[19] Chen R.J., Chen K.Y., Chang T.C., Sheu B.C., Chow S.N., Huang S.C.: “Prognosis and treatment of squamous cell carcinoma from a mature cystic teratoma of the ovary”. J. Formos Med. Assoc., 2008, 107, 857.

[20] Ohtani K., Sakamoto H., Masaoka N., Shimada K., Kanaeda T., Kurihara M., Nagai N., Satoh K.: “A case of rapidly growing ovarian squamous cell carcinoma successfully controlled by weekly paclitaxel-carboplatin administration”. Gynecol. Oncol., 2000, 79, 515.

[21] Chew I., Post M.D., Carinelli S.G., Campbell S., Di Y., Soslow R.A., Oliva E.: “p16 expression in squamous and trophoblastic lesions of the upper female genital tract”. Int. J. Gynecol. Pathol., 2010, 29, 513.

[22] Yoshioka T., Tanaka T.: “Immunohistochemical and molecular studies on malignant transformation in mature cystic teratoma of the ovary”. J. Obstet. Gynaecol. Res., 1998, 24, 83.